Skip to main content
Premium Trial:

Request an Annual Quote

Visiopharm, ISENET Partner to Promote Tissue Microarray Workflow

Premium

Visiopharm and Integrated Systems Engineering have agreed to comarket their products to researchers using tissue microarrays.

Integrated Systems Engineering, or ISENET, is a Milan-based company that offers a menu of tissue microarraying instruments called Galileo TMA CK. Visiopharm is a Hørsholm, Denmark-based firm that provides software for quantitative digital pathology. Visiopharm sells an analysis tool called Arrayimager that can produce a report based on data obtained from Galileo TMA CK systems and manage data, allowing users to search results based on donor identity, specific biomarkers, and other results.

Pasquale De Blasio, CEO of ISENET, said in a statement that the two firms aim to "provide the research and diagnostic communities with a TMA solution focused on quality, data integrity and results."

Both European companies maintain distributors in most major regional markets. Visiopharm has a partnership with Olympus to distribute Arrayimager in North and South America and Asia. ISENET relies on a number of distributors to reach customers in different European countries and also sells its systems direct worldwide from its headquarters in Italy.

Further details of the partnership were not discussed.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.